EP1230359A1 - Homologues de type chordine - Google Patents

Homologues de type chordine

Info

Publication number
EP1230359A1
EP1230359A1 EP00973208A EP00973208A EP1230359A1 EP 1230359 A1 EP1230359 A1 EP 1230359A1 EP 00973208 A EP00973208 A EP 00973208A EP 00973208 A EP00973208 A EP 00973208A EP 1230359 A1 EP1230359 A1 EP 1230359A1
Authority
EP
European Patent Office
Prior art keywords
clh
nucleic acid
acid sequence
sequence
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00973208A
Other languages
German (de)
English (en)
Inventor
Amir Toporoik
Sharon Biton
Kinneret Savitzky
Jeanne Bernstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compugen Ltd
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13284699A external-priority patent/IL132846A0/xx
Priority claimed from IL13376799A external-priority patent/IL133767A0/xx
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of EP1230359A1 publication Critical patent/EP1230359A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • SEQ ID NO: 1 The sequence shown in SEQ ID NO: 1 is a homolog to the known chordins within the VWFC domain, named after the von-Willebrand factor (VWF) type C repeat, which is found 2-4 times in these multi-domain proteins.
  • VWF domain has a length of about 70 amino acids covering 10 well conserved cysteines.
  • the present invention provides a nucleic acid molecule comprising or consisting of a non-coding sequence which is complementary to that of any one of SEQ ID NO: 1 to SEQ ID NO: 11, or complementary to a sequence having at least 70%, preferably 80%), most preferably 90% or 95% identity to said sequence or a fragment of said two sequences.
  • the complementary sequence may be a DNA sequence which hybridizes with any one of the sequences of SEQ ID NO: 1 to SEQ ID NO: 11, or hybridizes to a portion of that sequence having a length sufficient to inhibit the transcription of the complementary sequence.
  • compositions of the invention may be used also for the treatment of osteoporosis pseudoglioma syndrome, autosomal recessive osteopetrosis, and isolated increased bone mass (high bone mass without other clinical features).
  • the CLH of the invention may also be used for augmenting bone regeneration after injury, so as to speed up the healing process.
  • Alexander Disease This disorder, is characterized clinically by development of megalencephaly in infancy accompanied by progressive spasticity and dementia. In this disorder astrocytes show marked changes.
  • the amount of the antibody-antigen complex can be quantitized, in order to determine the level of the CHL-product or the anti-CHL antibodies, as the case may be.
  • Fig. 4a is the alignment of the third splice variant (SEQ ID NO: 15) with a known chordin deposited in the Emb under gi 4808227;
  • Fig. 13 shows the alignment of SEQ ID No. 19 to the known chordin deposited as gi 2731578;
  • Fig. 14 shows the alignment of SEQ ID No. 18 to the known chordin deposited as gi 3822218;
  • Fig. 15 shows the alignment of SEQ ID No. 20 to the known chordin deposited as gi 2731578;
  • Fig. 16 shows the alignment of SEQ ID No. 20 to the known chordin deposited as gi 382218;
  • Fig. 22 shows a Northern blot analysis of CLH expression in: skeletal muscles, uterus, colon, small intestine, bladder, heart, stomach, prostate;
  • the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E.coli.
  • the vector containing the appropriate DNA sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.
  • the expression of a sequence encoding CLH product may be driven by any of a number of promoters.
  • viral promoters such as the 35S and 19S promoters of CaMV (Brisson et al, Nature 310:511-514. (1984)) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu et al, EMBO J., 3:17-311, (1987)).
  • plant promoters such as the small subunit of RUBISCO (Coruzzi et al., EMBO J.
  • CLH product may also be expressed in an insect system.
  • Autographa cahfornica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
  • the CLH product coding sequence may be cloned into a nonessential region of the vims, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of CLH coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat.
  • the recombinant viruses are then used to infect S. frugiperda cells or Trichoplusia larvae in which CLH protein is expressed (Smith et al, J.
  • the probe is a nucleic acid molecule of at least 20 nucleotides, preferably 20-30 nucleotides, capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding CLH under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of CLH.
  • This assay can be used to distinguish between absence, presence, and excess expression of CLH product and to monitor levels of CLH expression during therapeutic intervention.
  • the substantially purified CLH product of the invention has been defined above as the product coded from the nucleic acid sequence of the invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à plusieurs variants d'épissage d'homologues de type chordine (CLH) ainsi qu'à leurs séquences d'acides nucléiques et d'acides aminés, à des vecteurs et à des cellules hôtes contenant lesdites séquences d'acides nucléiques et à des anticorps sensibles auxdites séquences d'acides aminés. Cette invention se rapporte à des compositions pharmaceutiques destinées au traitement de plusieurs maladies et contenant les séquences d'acides nucléiques, les séquences d'acides aminés, les vecteurs d'expression, les anticorps. Cette invention se rapporte également à des procédés de détection des séquences d'acides nucléiques ou d'acides aminés décrites ci-dessus ou dudit anticorps dans un échantillon biologique.
EP00973208A 1999-11-10 2000-11-10 Homologues de type chordine Withdrawn EP1230359A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL13284699 1999-11-10
IL13284699A IL132846A0 (en) 1999-11-10 1999-11-10 Novel nucleic acid and amino acid sequences
IL13376799A IL133767A0 (en) 1999-12-28 1999-12-28 Novel nucleic acid and amino acid sequences
IL13376799 1999-12-28
PCT/IL2000/000736 WO2001034796A1 (fr) 1999-11-10 2000-11-10 Homologues de type chordine

Publications (1)

Publication Number Publication Date
EP1230359A1 true EP1230359A1 (fr) 2002-08-14

Family

ID=26323900

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00973208A Withdrawn EP1230359A1 (fr) 1999-11-10 2000-11-10 Homologues de type chordine

Country Status (3)

Country Link
EP (1) EP1230359A1 (fr)
AU (1) AU1174501A (fr)
WO (1) WO2001034796A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525611A (ja) * 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−２分子およびその使用
AU2001249608A1 (en) * 2000-03-28 2001-10-08 Beth Israel Deaconess Medical Center Bladder cancer-specific peptides for diagnosis and therapy
WO2005014817A2 (fr) * 2003-08-07 2005-02-17 Compugen Ltd. Homologues de type chordine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6552198A (en) * 1997-03-14 1998-09-29 Human Genome Sciences, Inc. 28 human secreted proteins
WO2000012708A2 (fr) * 1998-09-01 2000-03-09 Genentech, Inc. Nouveaux pro-polypeptides et sequences correspondantes
DE19817946A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
JP2003525575A (ja) * 1998-05-07 2003-09-02 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 分泌蛋白およびそれらをコードするポリヌクレオチド
AU5475199A (en) * 1998-08-10 2000-03-06 Genetics Institute Inc. Human chordin-related proteins and polynucleotides encoding them
EP1179066A2 (fr) * 1999-05-19 2002-02-13 Incyte Genomics, Inc. Molecules de signalisation extracellulaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0134796A1 *

Also Published As

Publication number Publication date
AU1174501A (en) 2001-06-06
WO2001034796A1 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
US6342370B1 (en) Human slit polypeptide and polynucleotides encoding same
WO1999067382A2 (fr) Sequences d'un facteur de croissance apparente a l'angiopoietine
EP1159429A2 (fr) Nouvel acide nucleique et sequences d'acides amines
RU2420583C2 (ru) Композиции, реагенты, наборы и способы для диагностики, мониторинга и лечения ожирения и/или диабета
US20020061525A1 (en) Sequences of trail variants
US6783954B2 (en) VEGF nucleic acid and amino acid sequences
US6358702B1 (en) Polynucleotides encoding human Hox C10
US5654172A (en) Gabaa receptor epsilon subunit
US6573360B1 (en) Human ABH
WO2001034796A1 (fr) Homologues de type chordine
US20080027020A1 (en) Human Neuropeptide Receptor
AU5843600A (en) Splice variants of cd40-receptor
US6506884B1 (en) Variant of vascular endothelial growth factor
WO2000066728A1 (fr) Homologues de star
US20050281810A1 (en) Variants of alternative splicing
JP2002527104A (ja) Ｔｎｆｒ関連遺伝子１２
CA2337835A1 (fr) Compositions de polypeptides et de polynucleotides de canaux k
US20020081655A1 (en) Splice variant of mGluR
US20030105049A1 (en) StAR homologues
WO2001029215A2 (fr) Homologues de molecules d'adherence cellulaire neuronale
EP1105406A1 (fr) Nouveau polypeptide esk du canal potassium et compositions polynucleotidiques
WO2000044784A1 (fr) Sequences d'acide nucleique et d'acide amine
US20020068342A1 (en) Novel nucleic acid and amino acid sequences and novel variants of alternative splicing
EP1417310A2 (fr) Nouvelles sequences d'acides nucleiques et d'acides amines
EP1147183A1 (fr) Nouvelles sequences d'acides nucleiques et d'acides amines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BITON, SHARON

Inventor name: BERNSTEIN, JEANNE

Inventor name: SAVITZKY, KINNERET

Inventor name: TOPOROIK, AMIR

17Q First examination report despatched

Effective date: 20050608

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051220